Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

2Q Revenues: $11.7 billion (+3%)

2Q Earnings: $2.4 billion (-30%)*

YTD Revenues: $23.5 billion (flat)

YTD Earnings: $6.5 billion (+73%)**

Comments: Lipitor, Celebrex, Geodon and Lyrica performed well in the quarter: Lipitor sales were up 9% to $3.1 billion; Celebrex sales were $471 million, up 17%; Geodon sales were up 14% to $165 million and Lyrica sales were $271 million, up 38%. The company received approval/launched four products: Zeven, Eraxis, Exubera, and Chantix.

*Results for the quarter includes an impairment charge of $1.2 billion related to the developed technology rights and the write-off of machinery and equipment for Bextra. Results also include a merger-related in-process R&D expense write-off of $513 million related to the acquisition of Rinat Neurosciences Corp.

**YTD earnings include the tax provision related to the repatriation of foreign earnings of $1.7 billion. Results reflect the sale of the Consumer Healthcare business to Johnson & Johnson for approximately $16.6 billion, as discontinued operations.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters